Cannabis use is associated with increased levels of soluble gp130 in schizophrenia but not in bipolar disorder
A. Szabo, I. A. Akkouh, T. Ueland, T. Vik Lagerberg, I. Dieset, T. Bjella, P. Aukrust, S. Le Hellard, A.-K. Stavrum, I. Melle, O. A. Andreassen, S. Djurovic
This study finds that cannabis use is linked to higher soluble gp130 levels in schizophrenia patients but not in bipolar disorder patients, independent of immune cell modulation.
bioRxiv · Oct 15, 2019Pharmacology & Toxicology